Neuropeptides and Brain Function: Selank, Semax, DSIP, and Cognitive Research

What Are Neuropeptides?

Neuropeptides are small protein-like molecules (typically 3-100 amino acids) produced by neurons that act as signaling molecules in the nervous system. Unlike classical neurotransmitters (dopamine, serotonin, GABA), which are single amino acids or small molecules, neuropeptides are synthesized as larger precursor proteins (prepropeptides) that are cleaved into their active forms.

The human nervous system produces over 100 identified neuropeptides, which regulate virtually every aspect of brain function — mood, cognition, pain perception, appetite, sleep, stress responses, and neuroplasticity. Neuropeptides typically act at nanomolar concentrations (1000x lower than classical neurotransmitters) and produce effects that are slower in onset but longer in duration.

For peptide research, several synthetic and naturally-derived neuropeptides have become important research tools for studying cognitive function, neuroprotection, and neuroplasticity.

Selank: The Anxiolytic Neuropeptide

Background

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is based on the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory peptide derived from the heavy chain of immunoglobulin G.

Selank extends tuftsin’s sequence with a Pro-Gly-Pro tail — a modification that dramatically enhances metabolic stability (resisting enzymatic degradation) while adding anxiolytic and nootropic properties not present in the parent peptide.

Mechanism of Action

Selank modulates multiple neurotransmitter systems:

GABAergic system:

• Selank enhances the inhibitory tone of the GABAergic system without directly binding GABA receptors
• It modulates the expression of GABA transporter genes, affecting GABA reuptake
• This produces anxiolytic effects mechanistically distinct from benzodiazepines (which directly potentiate GABA-A receptor currents)

Monoamine modulation:

• Increases serotonin (5-HT) metabolism in the hypothalamus and frontal cortex
• Modulates dopamine and norepinephrine turnover
• These effects contribute to its mood-stabilizing and cognitive-enhancing properties

BDNF expression:

• Selank increases the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus
• BDNF is the primary neurotrophin supporting synaptic plasticity, long-term potentiation (LTP), and memory consolidation
• This BDNF-enhancing effect is considered central to Selank’s nootropic activity

Enkephalin system:

• Selank inhibits the enzymatic degradation of enkephalins (endogenous opioid peptides)
• This contributes to its anxiolytic and analgesic properties without the sedation or dependence associated with direct opioid receptor agonists

Clinical Evidence

Selank has been approved in Russia as an anxiolytic medication (nasal spray formulation, 0.15% solution). Key clinical findings:

• Reduced anxiety scores (Hamilton Anxiety Scale) comparable to medazepam, without sedation
• Improved cognitive performance (attention, memory) in anxious patients
• Enhanced adaptation to stress in healthy subjects under high-workload conditions
• No tolerance, dependence, or withdrawal effects observed

Administration

Selank is typically administered intranasally due to its small molecular weight and good nasal mucosal absorption. The intranasal route provides rapid CNS delivery via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier.

Semax: The Nootropic Neuropeptide

Background

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic peptide based on the N-terminal fragment (residues 4-10) of adrenocorticotropic hormone (ACTH). Like Selank, it was developed at the Institute of Molecular Genetics in Moscow and is approved in Russia as a nootropic and neuroprotective medication.

The ACTH(4-10) fragment was known to have cognitive-enhancing effects without the hormonal (adrenal-stimulating) activity of full-length ACTH. Semax extends this fragment with a Pro-Gly-Pro C-terminal tail for metabolic stability.

Mechanism of Action

Neurotrophic factor expression:

• Semax potently increases BDNF, NGF (nerve growth factor), and GDNF (glial-derived neurotrophic factor) expression
• This broad neurotrophic upregulation supports neuronal survival, synaptogenesis, and plasticity
• The BDNF increase is particularly pronounced in the hippocampus and prefrontal cortex — regions critical for learning and memory

Melanocortin system:

• As an ACTH fragment, Semax interacts with melanocortin receptors (MC3R, MC4R)
• Melanocortin signaling in the brain modulates attention, arousal, and memory consolidation
• This provides a distinct mechanism from Selank’s primarily GABAergic/serotonergic profile

Dopaminergic modulation:

• Semax enhances dopaminergic neurotransmission in the mesolimbic and mesocortical pathways
• This contributes to improved motivation, attention, and executive function
• The dopaminergic effects are modulatory (not direct agonism), avoiding the overstimulation risks of direct dopamine agonists

Neuroprotection:

• Semax reduces oxidative stress markers in neuronal tissue
• Inhibits nitric oxide synthase (NOS) overactivation, preventing excitotoxic damage
• Stabilizes the blood-brain barrier under ischemic conditions
• Reduces inflammatory cytokine expression in brain tissue

Clinical Evidence

Semax has been studied in several clinical contexts:

• Stroke recovery: Improved neurological outcomes when administered within 6 hours of ischemic stroke onset. Mechanisms include neuroprotection, enhanced neuroplasticity, and improved cerebral blood flow.
• Cognitive enhancement: Improved attention, memory, and mental performance in healthy subjects and in patients with cognitive impairment.
• Optic nerve atrophy: Intranasal Semax improved visual function in patients with optic nerve damage — attributed to neurotrophic factor upregulation.
• ADHD: Preliminary studies suggest improvements in attention and impulse control.

Administration

Like Selank, Semax is administered intranasally (0.1% or 1% solution). The intranasal route provides direct CNS access.

DSIP: Delta Sleep-Inducing Peptide

Background

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nine-amino-acid neuropeptide first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep. It was identified by its ability to induce delta-wave (slow-wave) sleep — the deepest, most restorative phase of the sleep cycle.

Despite its name, DSIP’s biology extends well beyond sleep induction. It is now understood as a stress-modulatory neuropeptide with effects on neuroendocrine regulation, pain perception, and oxidative stress defense.

Mechanism of Action

Sleep regulation:

• DSIP promotes delta-wave (stage 3-4 NREM) sleep — the phase associated with growth hormone release, tissue repair, and memory consolidation
• Does not suppress REM sleep (unlike benzodiazepines and many conventional sleep aids)
• Normalizes disrupted sleep architecture rather than inducing sedation — making it a sleep modulator rather than a sleep inducer

Neuroendocrine modulation:

• Modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing stress-induced cortisol release
• Influences LH (luteinizing hormone) and GH (growth hormone) secretion patterns
• Acts as a stress-buffering signal, reducing the neuroendocrine overactivation associated with chronic stress

Antioxidant effects:

• DSIP activates endogenous antioxidant defense systems (SOD, catalase, glutathione peroxidase)
• Reduces lipid peroxidation markers in brain tissue
• These effects are independent of its sleep-promoting activity and suggest a broader cytoprotective role

Pain modulation:

• DSIP has analgesic properties, possibly through modulation of opioid receptor sensitivity
• Reduces pain perception in chronic pain models without opioid-like side effects

Clinical Research

DSIP has been studied for:

• Insomnia and disrupted sleep architecture (normalized sleep patterns in chronic insomniacs)
• Chronic pain syndromes (reduced pain scores and analgesic medication requirements)
• Alcohol and opioid withdrawal (reduced withdrawal symptoms and normalized sleep)
• Stress-related disorders (reduced cortisol and improved stress tolerance)

Dihexa: The Hepatocyte Growth Factor Modulator

Background

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic oligopeptide derived from angiotensin IV that was developed at Washington State University by Joseph Harding and colleagues. It is notable for its extraordinary potency — active at picomolar concentrations, making it approximately 10 million times more potent than BDNF in promoting synaptogenesis.

Mechanism of Action

Dihexa’s primary mechanism involves hepatocyte growth factor (HGF) and its receptor c-Met:

• HGF/c-Met potentiation: Dihexa stabilizes HGF and enhances its binding to the c-Met receptor. HGF/c-Met signaling is a major pathway for neuronal survival, synapse formation, and dendritic spine growth in the brain.
• Synaptogenesis: In animal models, Dihexa increases the density of functional synapses in hippocampal and cortical neurons
• Memory enhancement: Dihexa-treated animals show improved performance in spatial memory tasks (Morris water maze, radial arm maze) and object recognition tests
• Blood-brain barrier crossing: Dihexa is orally bioavailable and crosses the BBB, unusual properties for a peptide

Comparing Neuropeptide Mechanisms

Peptide	Primary Target	Key Effect	Route	Onset
Selank	GABA/serotonin/BDNF	Anxiolytic + nootropic	Intranasal	Minutes
Semax	Melanocortin/BDNF/NGF	Nootropic + neuroprotective	Intranasal	Minutes
DSIP	Sleep architecture/HPA axis	Sleep normalization	SC injection	30-60 min
Dihexa	HGF/c-Met	Synaptogenesis	Oral/SC	Hours

The Blood-Brain Barrier Challenge

A fundamental challenge in neuropeptide research is delivering peptides across the blood-brain barrier (BBB). The BBB is a highly selective semipermeable membrane formed by tight junctions between brain endothelial cells that prevents most circulating molecules from entering brain tissue.

Strategies for CNS delivery of neuropeptides:

1. Intranasal administration: Bypasses the BBB via olfactory and trigeminal nerve pathways. Used for Selank and Semax. Delivers peptides directly to the CNS within minutes.
2. Small molecular size: Peptides under ~500 Da may cross the BBB to some degree via passive diffusion. Dihexa’s small size and lipophilicity enable oral bioavailability and BBB crossing.
3. Receptor-mediated transcytosis: Some peptides bind to receptors on brain endothelial cells and are transported across via vesicular transcytosis.
4. Lipidation: Attaching fatty acid chains can improve BBB penetration for some peptides.

The intranasal route has become the standard for neuropeptide research because it provides rapid, direct CNS access without the need for chemical modification of the peptide.

Neurotrophic Factors: The Common Thread

A recurring theme across neuropeptide research is the modulation of neurotrophic factors — proteins that support neuronal survival, growth, and plasticity:

• BDNF (Brain-Derived Neurotrophic Factor): Upregulated by both Selank and Semax. Supports synaptic plasticity, long-term potentiation, and memory consolidation. BDNF decline is associated with depression, cognitive decline, and neurodegenerative disease.
• NGF (Nerve Growth Factor): Upregulated by Semax. Essential for cholinergic neuron survival in the basal forebrain — the neuronal population most affected in Alzheimer’s disease.
• GDNF (Glial-Derived Neurotrophic Factor): Upregulated by Semax. Promotes survival of dopaminergic neurons — relevant to Parkinson’s disease research.
• HGF (Hepatocyte Growth Factor): Potentiated by Dihexa. Promotes synaptogenesis and dendritic spine formation.

The ability of neuropeptides to upregulate multiple neurotrophic factors simultaneously distinguishes them from small-molecule nootropics, which typically target a single receptor or enzyme.

Frequently Asked Questions

What is the difference between Selank and Semax?

Selank is primarily anxiolytic (anti-anxiety) with secondary nootropic effects, working through GABAergic and serotonergic modulation. Semax is primarily nootropic (cognitive-enhancing) and neuroprotective, working through the melanocortin system and neurotrophic factor upregulation. They target different but complementary pathways and are sometimes studied in combination.

Can DSIP help with jet lag or shift work sleep disruption?

DSIP normalizes disrupted sleep architecture rather than forcing sleep, making it theoretically relevant to circadian disruption research. However, clinical evidence specifically for jet lag or shift work is limited. DSIP’s mechanism (promoting delta-wave sleep without suppressing REM) is better suited to chronic sleep architecture disruption than acute circadian phase shifts.

How do intranasal neuropeptides reach the brain?

Intranasal administration delivers peptides to the olfactory epithelium (roof of the nasal cavity), from which they can travel along the olfactory nerve directly to the olfactory bulb and then to wider brain regions. A second pathway involves the trigeminal nerve, which provides sensory innervation to the nasal cavity and projects to the brainstem and beyond. Both pathways bypass the blood-brain barrier entirely.

Are neuropeptides the same as nootropics?

Not exactly. “Nootropic” is a functional category (substances that enhance cognition), while “neuropeptide” is a structural category (peptides active in the nervous system). Some neuropeptides are nootropic (Semax, Selank), but neuropeptides also include non-nootropic molecules like substance P (pain signaling) and oxytocin (social bonding). Conversely, many nootropics are not peptides (e.g., racetams, caffeine, modafinil).

What is the significance of BDNF upregulation?

BDNF is often described as “fertilizer for the brain.” It supports synaptic plasticity (the ability of synapses to strengthen or weaken in response to activity), long-term potentiation (the cellular basis of learning), and neuronal survival. Low BDNF levels are associated with depression, anxiety, cognitive decline, and neurodegenerative diseases. Interventions that increase BDNF (exercise, certain neuropeptides, some antidepressants) tend to improve mood and cognitive function across multiple contexts.

References

1. Semenova TP, et al. “Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.” Neurosci Behav Physiol. 2009;39(8):853-860.
2. Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2005;30(12):1493-1500.
3. Dolotov OV, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Res. 2006;1117(1):54-60.
4. Kastin AJ, et al. “DSIP — more than a sleep peptide?” Trends Pharmacol Sci. 1984;5:328-331.
5. Harding JW, et al. “Development of small-molecule ligands and peptides targeting HGF/c-Met for cognitive enhancement.” J Pharmacol Exp Ther. 2013;344(2):431-440.
6. Kozlovskii II, Danchev ND. “The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats.” Neurosci Behav Physiol. 2003;33(7):639-643.
7. Levitskaya NG, et al. “Nootropic and anxiolytic effects of heptapeptide Selank.” Eksp Klin Farmakol. 2008;71(5):8-12.
8. McCoy AT, et al. “Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.” J Pharmacol Exp Ther. 2013;344(1):141-154.